Vertex Pharmaceuticals Stock Performance
VRTX Stock | USD 393.48 0.38 0.1% |
The entity has a beta of 0.69, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vertex Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vertex Pharmaceuticals is expected to be smaller as well. Vertex Pharmaceuticals has an expected return of -0.16%. Please make sure to validate Vertex Pharmaceuticals kurtosis, as well as the relationship between the rate of daily change and price action indicator , to decide if Vertex Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vertex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.27) | Five Day Return (0.88) | Year To Date Return (4.33) | Ten Year Return 500.43 | All Time Return 8.6 K |
Last Split Factor 2:1 | Last Split Date 2000-08-24 |
1 | Vertex Pharmaceuticals Beats Stock Market Upswing What Investors Need to Know | 03/18/2024 |
2 | Vertex trust sells shares worth over 88,000 | 03/25/2024 |
3 | Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 23 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease | 04/01/2024 |
4 | Spire Wealth Management Top Holdings and 13F Report | 04/05/2024 |
5 | Orca Security Named Google Cloud Generative AI Partner | 04/08/2024 |
6 | Vertex to Announce First Quarter 2024 Financial Results on May 6 | 04/09/2024 |
7 | Vertex Pharmaceuticals Registers a Bigger Fall Than the Market Important Facts to Note | 04/10/2024 |
8 | Vertex Pharmaceuticals Buy, Sell, or Hold | 04/11/2024 |
9 | Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer | 04/15/2024 |
10 | CRISPR Therapeuticss Options Frenzy What You Need to Know | 04/17/2024 |
Begin Period Cash Flow | 10.5 B |
Vertex |
Vertex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 43,502 in Vertex Pharmaceuticals on January 19, 2024 and sell it today you would lose (4,329) from holding Vertex Pharmaceuticals or give up 9.95% of portfolio value over 90 days. Vertex Pharmaceuticals is currently does not generate positive expected returns and assumes 1.2071% risk (volatility on return distribution) over the 90 days horizon. In different words, 10% of stocks are less volatile than Vertex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Vertex Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vertex Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vertex Pharmaceuticals, and traders can use it to determine the average amount a Vertex Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1318
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | VRTX |
Estimated Market Risk
1.21 actual daily | 10 90% of assets are more volatile |
Expected Return
-0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vertex Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vertex Pharmaceuticals by adding Vertex Pharmaceuticals to a well-diversified portfolio.
Vertex Pharmaceuticals Fundamentals Growth
Vertex Stock prices reflect investors' perceptions of the future prospects and financial health of Vertex Pharmaceuticals, and Vertex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vertex Stock performance.
Return On Equity | 0.23 | ||||
Return On Asset | 0.13 | ||||
Profit Margin | 0.37 % | ||||
Operating Margin | 0.38 % | ||||
Current Valuation | 91.41 B | ||||
Shares Outstanding | 258.46 M | ||||
Price To Earning | 24.57 X | ||||
Price To Book | 5.83 X | ||||
Price To Sales | 10.38 X | ||||
Revenue | 9.84 B | ||||
Gross Profit | 5.32 B | ||||
EBITDA | 3.93 B | ||||
Net Income | 3.62 B | ||||
Cash And Equivalents | 9.77 B | ||||
Cash Per Share | 38.06 X | ||||
Total Debt | 808.4 M | ||||
Debt To Equity | 0.06 % | ||||
Current Ratio | 4.70 X | ||||
Book Value Per Share | 68.22 X | ||||
Cash Flow From Operations | 3.54 B | ||||
Earnings Per Share | 13.87 X | ||||
Market Capitalization | 101.88 B | ||||
Total Asset | 22.73 B | ||||
Retained Earnings | 10.14 B | ||||
Working Capital | 10.6 B | ||||
Current Asset | 1.41 B | ||||
Current Liabilities | 506.35 M | ||||
About Vertex Pharmaceuticals Performance
To evaluate Vertex Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Vertex Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Vertex Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Vertex Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Vertex's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 213.64 | 110.53 | |
Return On Tangible Assets | 0.17 | 0.18 | |
Return On Capital Employed | 0.20 | 0.21 | |
Return On Assets | 0.16 | 0.17 | |
Return On Equity | 0.21 | 0.22 |
Things to note about Vertex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vertex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vertex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Vertex Pharmaceuticals generated a negative expected return over the last 90 days | |
Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
Over 97.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from benzinga.com: CRISPR Therapeuticss Options Frenzy What You Need to Know |
- Analyzing Vertex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vertex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vertex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vertex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vertex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vertex Pharmaceuticals' stock. These opinions can provide insight into Vertex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Stocks Directory Find actively traded stocks across global markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.87 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.